A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients.
As with other second-generation antidepressants, the antidepressive efficacy of mianserin was investigated in double-blind control group studies, mostly under outpatient conditions. This study tested the antidepressive efficacy and safety of mianserin as compared to amitriptyline in a sample of 51 depressed inpatients suffering from major depression. No statistically significant difference was found with regard to the main efficacy outcome criterion, the HAMD. The tolerability results demonstrated a superiority of mianserin with respect to vegetative symptoms and especially with respect to dryness of the mouth.
Möller
H J
HJ
Department of Psychiatry, Ludwig Maximilians University, Munich, Germany.
Kasper
S
S
Müller
H
H
Kissling
W
W
Fuger
J
J
Ruhrmann
S
S
D000328:Adult; D000639:Amitriptyline / Q000009:adverse effects / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010352:Patient Dropouts; D011569:Psychiatric Status Rating Scales
D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D000639:Amitriptyline; D008803:Mianserin